Experts Published New Cancer Trial Reporting Standards
Guidelines seek to improve how clinical trials capture patient quality of life and treatment side effects.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Should cancer clinical trials prioritize patient-reported quality of life data when evaluating new treatments?
Common Sense Oncology and the European Organisation for Research and Treatment of Cancer have released new recommendations for reporting quality of life data in oncology clinical trials. The guidance aims to provide patients and clinicians with clearer insights into treatment-related deterioration.
Why it matters
Current reporting methods often fail to reflect the full patient experience regarding daily functioning and side effects. These standards ensure that negative quality of life outcomes are explicitly documented alongside traditional clinician-reported toxicity data.
The guidelines, identified by DOI 10.1016/S1470-2045(26)00333-5, mandate reporting the duration and proportion of patients experiencing clinically meaningful deterioration in quality of life.
The players
Common Sense Oncology
This is a global movement of clinicians and researchers dedicated to ensuring that cancer treatments are based on the best evidence and prioritize outcomes that matter to patients.
European Organisation for Research and Treatment of Cancer
This organization is a non-profit research institution based in Europe that coordinates and conducts international clinical trials to improve the standards of cancer care.
The details
The review advocates for the integration of validated patient-reported outcome measures within the primary publication of trial results. Researchers are urged to conduct regular assessments of patient well-being throughout the duration of treatment and subsequent follow-up periods.
Timeline
The policy review was officially published on October 1, 2026.
The Big Picture
This guidance follows the standards set by The Lancet Oncology policy review to redefine success in oncology trials away from purely clinical endpoints.
These standards aim to help patients and their doctors make better-informed decisions by providing transparent data on how a treatment may impact daily quality of life. Patients may gain a more realistic understanding of potential treatment burdens beyond standard clinical toxicity reports.
The takeaway
Clinical research is shifting to prioritize the patient's daily functional experience over purely physiological data. Patients should consult with their providers to understand how these new reporting standards might impact the clarity of information presented for their specific treatment plans.
Further reading
For more information on the evolution of oncological standards, visit the Cancer section.
More information
Access the full policy review in The Lancet00333-5/abstract) for detailed methodology.
Source note: This article includes information reported by News-Medical.
Live Poll
Should cancer clinical trials prioritize patient-reported quality of life data when evaluating new treatments?
